Persistent Atrial Fibrillation Clinical Trial
Official title:
The Effect of Cryoballoon and Radiofrequency Ablations on Left Atrial Structural and Electrical Remodeling in Patients With Drug-refractory Persistent Atrial Fibrillation
A total of 106 patients with drug-refractory persistent atrial fibrillation, who are planned to undergo circumferential pulmonary vein isolation (CPVI), will be randomly allocated into two groups. These patients will receive cryoballoon ablation, radiofrequency ablation under the guidance of 3D mapping respectively (allocation ratio, 1:1). Atrial electrical activity including atrial effective refractory period, atrial conduction time, electromechanical conduction time, P wave dispersion and spatial dispersion of atrial refractory will be measured before and after the operation. Left atrial appendage flow velocity of all patients are measured by Transesophageal Echocardiography(TEE) 24 hours before the operation. Real-time ultrasound examinations of left atrial function are carried out for all patients before the operation and after the operation. Blood samples are extracted in all patients before the operation and after the operation.This study will clarify whether these different operation methods have different effects on the recovery of postoperative left atrial function and electrical activity in patients with persistent atrial fibrillation, and whether changes in left atrial function electrical activity are related to indicators such as inflammation, blood clotting and myocardial injury. Cryoballoons ablation is still less used to operate on persistent atrial fibrillation. To investigate the ablative effect, electrical remodeling and structural remodeling of persist atrial fibrillation with different operating methods. Therefore, the ablation is related indicators such as the success rate of the operation, intraoperative complications, postoperative recurrence rate and the amount of x-ray exposure are compared among two groups. At the same time, biochemical indicators of inflammation, blood clotting and myocardial injury such as blood routine, myocardial enzyme, BNP, troponin I and D-D dimmer are detected to analyze and determine which indicators are related to the postoperative recurrence of atrial fibrillation, the recovery of postoperative left atrial function.
From February 2018 to February 2020, the investigators enroll consecutive patients with
drug-refractory persistent atrial fibrillation who were scheduled for an initial catheter
ablation.Patients are divided in to two group: persistent AF in radiofrequency ablation
group, cryoballoon ablation group.
1. Radiofrequency ablation group: Each patient randomly allocated into the radiofrequency
ablation group receives circumferential pulmonary vein isolation(CPVI), if atrial
flutter is diagnosed before and during operation,then a radiofrequency is used to ablate
cavo-tricuspid isthmus. Under the 3D electro-anatomical mapping system (Carto 3,
Biosense Webster), after passing through the transseptal sheath, the ablation catheter
is infused under pressure to enter into the left atrium to carry out radiofrequency
ablation.The default strategy is to create a circle surrounding the two ipsilateral
pulmonary veins. The cardioversion is performed if spontaneous conversion is not
observed after CPVI. Observation is carried out for 20-30 minutes after the entrance and
exit block of pulmonary vein potentials,in the meantime investigators will mapping the
left atrial substrate. If mapping system detect a poor substrate,the investigators
should continue to ablate for left atrial roof and posterior line.The situation of
pulmonary vein potential conduction will be detected again. If there is a recovery,
ablation will be continuously carried out.
2. Cryoballoon ablation group: Cryoablation is performed using a single cryoballoon. The
diameter of the cryoballoon (Arctic Front Advance™ Cardiac CryoAblation Catheter;
Medtronic, Minneapolis, MN) is determined as 28 mm or 23 mm according to pulmonary
venography results. After passing through the transseptal sheath, the cryoballoon
catheter enters into the left atrium and is continuously infused with heparin saline
through a 15F oriented sheath. The balloon is inflated at the entrance of the pulmonary
vein. The mapping confirms that the balloon blocks the entrance of the pulmonary vein.
After blocking of the entrance of the pulmonary vein is enhanced, liquid nitrogen is
injected for cryoablation. Before performing right pulmonary vein ablation, a secondary
catheter is placed into the superior vena cava during the cryoablation. A cycle length
of 999 ms is taken to continuously make the right phrenic nerve pulsate. If diaphragm
movement is weakened or disappears, the cryoablation will be immediately stopped. In
general, the cryoablation of each pulmonary vein is carried out twice. According to the
objective condition, the operator determine whether or not to carry out an additional
cryoablation. The cardioversion is performed if spontaneous conversion is not observed
after CPVI. Then investigators will applicate electrophysiological substrate mapping for
guiding ablation of atrial fibrillation,If mapping system detect a poor substrate,
investigators should continue to ablate for left atrial roof and posterior line. By
testing the entrance and exit block of pulmonary vein potentials,the investigators
observe the duration of potentials.
3. All patients fill the follow-up form before operation. After catheter ablation therapy,
all patients invited to come back to the outpatient clinic every week in the first
month, and then at 2, 3, 6, 9, and 12 month to follow up. Patients received
electrocardiogram and Holter monitor examination if with symptoms of palpitations. Those
patients with no symptoms received electrocardiogram every month and Holter monitor
examination every 6 months. Recurrence of atrial fibrillation was defined as atrial
fibrillation/flutter or atrial tachycardia lasting ≥ 30 seconds 3 months after ablation
therapy. Atrial electrical activity including atrial effective refractory period, atrial
conduction time, electromechanical conduction time, P wave dispersion and spatial
dispersion of atrial refractory will be measured before and after the operation.Blood
samples (routine blood, high sensitivity c-reactive protein,B-type natriuretic peptide
(BNP), cystatin C,homocysteine,β2-microglobulin) and transthoracic echocardiography
indexes (left atrial anterior to posterior diameter, left atrial length-diameter,left
atrial transverse-diameter,left atrial volume index, mitral e', E peak, A peak,
E/A,velocity time integral (VTI), left atrial ejection fraction, left atrial strain,
strain rate and atrial electrical - mechanical conduction time) are recorded in all
patients at each follow-up. Patients with AF recurrence must have an electrocardiogram
or a 24 hour holter monitor evidence.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05970120 -
A Study of Intracardiac Ultrasound With the NUVISION NAV Ultrasound Catheter
|
N/A | |
Recruiting |
NCT05416086 -
iCLAS™ Cryoablation System Post-Market Clinical Follow-up (PMCF) Study
|
N/A | |
Completed |
NCT03650556 -
Safety and Effectiveness of TactiCath™ Contact Force, Sensor Enabled™ (TactiCath SE) Catheter for Ablation of Drug Refractory, Symptomatic, Persistent Atrial Fibrillation
|
N/A | |
Recruiting |
NCT04085731 -
Driver-guided Ablation of Persistent Atrial Fibrillatiom
|
||
Withdrawn |
NCT02344394 -
Comparison of Hybrid Ablation and Pulmonary Vein Isolation Alone vs Hybrid Ablation With PVI Plus Catheter Ablation
|
N/A | |
Terminated |
NCT01683045 -
Efficacy and Safety Study of the Estech COBRA® Surgical System to Treat Patients With a History of Irregular Heart Beats
|
N/A | |
Completed |
NCT01694563 -
ABLATE Post Approval Study - Synergy Ablation Lesions for Non-Paroxysmal Atrial Fibrillation
|
N/A | |
Active, not recruiting |
NCT03643224 -
DiamondTemp™ System for the Treatment of Persistent Atrial Fibrillation
|
N/A | |
Withdrawn |
NCT05093868 -
Electrographic Flow Mapping Validation in Patients With Persistent Atrial Fibrillation (EVAL AF)
|
N/A | |
Completed |
NCT05152966 -
Feasibility Study of the FARAPULSE™ Cardiac Ablation System Plus in the Treatment of Persistent Atrial Fibrillation(PersAFOne II)
|
N/A | |
Completed |
NCT05043883 -
Automated Assessment of PVI Using a Novel EP Recording System
|
N/A | |
Completed |
NCT04022954 -
HD Mapping of Atrial Fibrillation in Asia Pacific
|
||
Active, not recruiting |
NCT06124690 -
Persistent Atrial Fibrillation Without the Evidence of Low-voltage Areas
|
N/A | |
Completed |
NCT06260670 -
FLOW EVAL-AF: FLOW Mapping Electrogram VALidation in Patients With Persistent Atrial Fibrillation
|
N/A | |
Not yet recruiting |
NCT05454111 -
CARTO-Finder Guided Ablation Versus Multiscale Entropy Guided Ablation in Persistent Atrial Fibrillation
|
N/A | |
Active, not recruiting |
NCT05077670 -
Hybrid Characterization of Driver Sites During Atrial Fibrillation and Sinus Rhythm
|
||
Withdrawn |
NCT03835338 -
WATCHMAN for Concomitant Left Atrial Appendage Electrical Isolation and Occlusion to Treat Persistent Atrial Fibrillation Rhythm
|
N/A | |
Completed |
NCT02275104 -
Multimodal Image Processing Software to Guide Cardiac Ablation Therapy
|
N/A | |
Not yet recruiting |
NCT05565183 -
Combined Study of ATrial Strain and Voltage by High Density Mapping in Young Patients With Atrial Fibrillation.
|
N/A | |
Completed |
NCT02274857 -
Randomized Evaluation of Atrial Fibrillation Treatment With Focal Impulse and Rotor Modulation Guided Procedures
|
N/A |